In order to participate in the conference call, please dial 1-877-407-9170 (US Domestic toll-free). International dial-in numbers and an audio webcast can be accessed under "Events & Presentations" through the Investors & Media section of the Prosensa corporate website at www.prosensa.com.
About Prosensa Holding N.V.
Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy and Huntington's Disease.
Prosensa's current portfolio includes six compounds for the
treatment of DMD, all of which have received orphan drug status in
CONTACT: Prosensa Holding N.V.
Celia Economides, Senior Director IR & Corporate Communications Phone: +1 917 941 9059 Email: firstname.lastname@example.org
News Provided by Acquire Media